Tryp Therapeutics Inc.

Recent News

  • Tryp Therapeutics Reports on Key Milestones for 2021

    San Diego, California--(Newsfile Corp. - April 20, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, reported today on the Company's significant progress since successfully completing its Initial Public Offering in December 2020.Tryp is advancing two drug development platforms: Psilocybin-for-Neuropsychiatric Disorders (PFNTM) targeting chronic pain and eating disorders; and razoxane for soft tissue sarcomas. Both platforms are based on chemistries...

    2021-04-20 7:00 AM EDT
  • Tryp Therapeutics to Host Investor Day on April 22

    San Diego, California--(Newsfile Corp. - April 15, 2021) -  Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it will be hosting its quarterly Investor Day on Thursday, April 22 at 9:00 a.m. PDT.Tryp would like to invite all current shareholders and prospective investors to connect directly with Tryp's management team to discuss many of the Company's achievements since...

    2021-04-15 7:00 AM EDT
  • Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

    San Diego, California--(Newsfile Corp. - April 5, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company") a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today it has initiated quoting activity on the OTCQB® Venture Market (the "OTCQB") and is eligible for settlement and transfer of its common shares in the United States with The Depository Trust Company ("DTC"). The Company's common shares are currently quoted on the OTCQB under...

    2021-04-05 12:38 PM EDT
  • Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

    San Diego, California--(Newsfile Corp. - April 1, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has amended the terms of its stock option plan (the "Plan") and granted stock options (the "Options") to a director of the Company.The Plan was amended to: (i) permit the cashless exercise of Options; and (ii) to increase the number of shares...

    2021-04-01 9:48 PM EDT
  • Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

    San Diego, California--(Newsfile Corp. - April 1, 2021) -  Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg McKee as its Chief Executive Officer. Mr. McKee will also continue in his responsibilities as Chairman of the Board of Directors of the Company.Mr. McKee has extensive experience leading publicly traded pharmaceutical companies and brings a vast network...

    2021-04-01 7:00 AM EDT
  • Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

    La Jolla, California--(Newsfile Corp. - March 18, 2021) -  Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today that it has submitted a provisional patent (US 63/161,070) to improve how psychedelics are administered across a broad range of indications.The provisional patent describes novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction in the time spent by patients in the dissociative state. These proprietary...

    2021-03-18 5:00 AM EDT
  • Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

    La Jolla, California--(Newsfile Corp. - March 9, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that it has appointed Luke Hayes as its Chief Financial Officer.Mr. Hayes has been active in the life science industry for more than 20 years with experience in technology transfer, venture capital, and finance. He started his career doing business development...

    2021-03-09 8:53 PM EST
  • Tryp Therapeutics Announces Application to List on OTCQB

    La Jolla, California--(Newsfile Corp. - March 4, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today that it has submitted its application for a listing to the OTCQB® Venture Market ("OTCQB").The Financial Industry Regulatory Authority or FINRA has accepted the Company's Form 211, which qualifies the Company's shares to trade in the United States on the OTC Pink Market under...

    2021-03-04 10:00 AM EST